Molecular Therapy Oncology

Intrinsic immunosuppressive features of monocytes suppress CAR-T19 through IL-1 pathway modulation in mantle cell lymphoma.

CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors.

Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin.

Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs.

Tumor-specific cytosol-penetrating antibodies for antigen- and TME-dependent intracellular cargo delivery.

Preclinical study of inetetamab combined with atezolizumab to synergistically inhibit HER2 and PD-L1 in the treatment of ovarian cancer

伊尼妥单抗联合阿替利珠单抗协同抑制HER2及PD-L1治疗卵巢癌的临床前研究

Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade

使用患者来源的器官型肿瘤球体测试病毒载体基因治疗与检查点阻断的联合作用

Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML

发现和临床前开发基于 SdAb 的 CAR-T 技术，用于 AML 中的 CD33 靶向治疗

Targeted treatment of chondrosarcoma with a bacteriophage-based particle delivering a secreted tumor necrosis factor-related apoptosis-inducing ligand

使用基于噬菌体的颗粒递送分泌的肿瘤坏死因子相关凋亡诱导配体对软骨肉瘤进行靶向治疗

Cell-derived Newcastle disease virus variant with two amino acid substitutions near cleavage site of F shows favorable traits as oncolytic virus

细胞衍生的鸡新城疫病毒变体在 F 的裂解位点附近发生两次氨基酸替换，显示出作为溶瘤病毒的良好特性